Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DDU5 | ISIN: SE0015244884 | Ticker-Symbol: P52
Frankfurt
21.11.24
09:59 Uhr
0,238 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NEWBURY PHARMACEUTICALS AB Chart 1 Jahr
5-Tage-Chart
NEWBURY PHARMACEUTICALS AB 5-Tage-Chart
GlobeNewswire (Europe)
31 Leser
Artikel bewerten:
(0)

Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2023 - February 2024

Finanznachrichten News

Quarter 2, December 2023 - February 2024
· Net revenue was 3 135 (1 501) tkr.
· EBITDA was -4 147 (-4 550) tkr.
· Operating cash flow was -7 977 (-5 849) tkr.

Interim period, September 2023 - February 2024
· Net revenue was 14 320(1 759) tkr.
· EBITDA was -6 881 (-9 992) tkr.
· Operating cash flow was -13 655 (-11 064) tkr.
· Cash position in the end of period was 6 412 (21 157) tkr.
· Licensed products at the end of period were 31 (33).
· Products with distribution rights at the end of the period were 12 (2).
· Products with marketing authorization in the end of the period were 20 (8).
· Products launched in Nordics at end of the period 6 (2).

Significant events during the quarter
· The annual general meeting of Newbury Pharmaceuticals was held on 10 January 2024. The Board was re-elected with Karl Karlsson as chairman.
· Nintedanib Newbury approved by the Swedish Health Authorities.
· Newbury subsidiary based in Switzerland receives international sales order valued at 8,8 mkr.

Significant events after the end of the quarter
· Newbury carries out a directed share issue of approximately 19 mkr at a subscription price on 4 kr per share. After the Share Issue, the number of outstanding shares in Newbury increases by 4 737 500 shares, from 19 521 154 to 24 258 654 shares.
A word from the CEO

Sales in Q2
Sales is solidly growing compared to same period previous year with +108% growth in this quarter and year-to-date growth of 714%. However, as anticipated, the turnover was somewhat lower this quarter compared to previous quarter reflecting the irregular flow of orders and fluctuations in sales. It is nice to witness the commercial progress despite a quarter with modest sales.

For the same reasons, it was a pleasure to announce an order totalling 8,8 MSEK to be despatched by the end of May 2024.

Advancing the portfolio
Compared to previous year, we have enlarged the portfolio to 43 products with either licensed or distribution rights and expect to continue enlarging the portfolio through licenses or distribution rights.

We recently obtained regulatory approval in Sweden for Nintedanib Newbury - a product used for the treatment of idiopathic pulmonary fibrosis. By now we have 20 registered products across Scandinavia and additionally nine products are currently submitted for approval.

The expansion of the Nordic portfolio continues with several launches planned in 2024. At the same time, we see recurring orders from the international sales activities which is a strong foundation for continued growth. We have a good foundation for continued growth and will pursue to broaden the business during the coming months with more launches, more product approvals and potentially new partnerships.

Directed share issue
At the annual meeting in January the board was re-elected with Karl Karlsson as chairman. At the same time, the board where given authorization to decide to issue new shares in the company, in accordance with the board's proposal.

On March 4th the company announced a successful directed issue raising app. 19 MSEK from a few new investors together with a few existing shareholders.

The directed issue will enable Newbury to continue advance and expand the portfolio of in-licensed products and secures funding for the regulatory fees to authorities relating to new product approvals and the expenses relating to launching of more products.

I welcome new shareholders as well thank existing shareholders for the trust in the continued growth of Newbury Pharmaceuticals. We are pleased with a strengthening of our capital base which will secure the continued focus on executing our growth plans by launching additional products and building a stronger company for the future.

The report is publised on Newbury Pharmaceuticals website:
https://www.newburypharma.com/investors/financial-information/

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

This information is information that Newbury Pharmaceuticals is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-10 08:00 CEST.

© 2024 GlobeNewswire (Europe)
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.